Alloy Therapeutics funding, news & analysis

Unlock Full Access Sign In

Home > Companies > Alloy Therapeutics

Alloy Therapeutics

Drug discovery platform and services for antibody, TCR mimic, and oligonucleotide therapeutics

#biotechnology

Funding

$136.24M

2022

Details

Headquarters

Boston, United States

CEO

Errik Anderson

Website

Milestones

FOUNDING YEAR

2017

Listed In

#biotechnology

Date	Event	Valuation	Amount	Price	Status
Oct 2022	Series D Sources Alloy Therapeutics raised $42M Series D at $736.24M valuation alloytx.com Alloy Therapeutics raised $42M Series D at $736.24M valuation forgeglobal.com	$736.2M	$42.0M	$26.17	Closed
Share Classes Series D Preferred Issue Price: $21.15 Recorded date: Oct 2022 Series E-2 Preferred Issue Price: $20.94 Recorded date: Mar 2026 Series E-1 Preferred Issue Price: $26.17 Recorded date: Mar 2026
Unlock Alloy Therapeutics data Sign up for data access
Apr 2021	Series C	—	—	—	Closed
Jun 2020	Series B	—	—	—	Closed

Details

Headquarters

Boston, United States

CEO

Errik Anderson

Website

Milestones

FOUNDING YEAR

2017

Listed In

#biotechnology